Anticholinesterase and anticholinergic poisoning

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1824 times

Anticholinesterase and anticholinergic poisoning

Michael J. Murray, MD, PhD

Anesthesia providers are likely to assist in caring for patients with anticholinesterase poisoning either because of their knowledge of cholinergic pharmacology and physiology or because of their expertise in managing the airway and ventilators.

Anticholinesterase poisoning

Anticholinesterase drugs inhibit AChE, thereby increasing the concentration of ACh at cholinergic sites; the excess ACh results in prolonged stimulation of muscarinic and nicotinic receptors. Anesthesia providers use carbamates, anticholinesterase drugs such as neostigmine, to reverse the effects of neuromuscular blocking agents at the end of a procedure. The muscarinic side effects of neostigmine are mitigated by simultaneously infusing an anticholinergic agent, such as atropine or glycopyrrolate, with the neostigmine.

Pesticides (with the exception of sevin, a carbamate) and the chemical nerve agents are organophosphate compounds, irreversible inhibitors of AChE; once released, ACh remains at its site of action, resulting in prolonged stimulation of muscarinic and nicotinic receptors. Muscarinic signs and symptoms include salivation, lacrimation, urination, diaphoresis, gastrointestinal upset, and emesis (i.e., the mnemonic SLUDGE; or DUMBELS—diarrhea, urination, meiosis, bronchorrhea/bronchoconstriction, emesis, lacrimation, salivation). Bradycardia (or tachycardia) and hypotension are signs of severe poisoning, as are confusion and shock. Nicotinic effects occur at the neuromuscular junction; skeletal muscle initially fasciculates and then becomes weak or paralyzed because the myofibril cell membrane is unable to repolarize (Box 83-1). Severe reactions, termed cholinergic crisis, may lead to ventilatory failure and death within minutes to hours following exposure.

Therapy

When treating organophosphate poisoning, the first line of therapy is termination of exposure (e.g., relocating the patient and removing contaminated clothing). If the patient has come in contact with the organophosphate, as opposed to inhaling the vapor of the anti-AChE, the patient should undergo a “wet” decontamination, being washed with copious amounts of water and 0.5% hypochlorite (active agent in household bleach). The severity of the poisoning can be classified as mild, moderate, or severe based on the symptoms and signs of exposure (Table 83-1).

Table 83-1

Signs and Symptoms of Anticholinesterase Poisoning Based on Severity

Mild Moderate Severe
Headache
Meiosis
Rhinorrhea
Salivation
Same as for mild,
PLUS:
Rhinorrhea is severe
Dyspnea
Muscle fasciculations
Same as for moderate,
PLUS:
Severe respiratory difficulty
Urinary incontinence
Weakness, paralysis
Convulsions

Pharmacologic intervention to reverse muscarinic symptoms for patients with moderate to severe poisoning includes 2 to 4 mg of intravenously administered atropine, a competitive muscarinic antagonist (repeated as needed). No nicotinic antagonists exist; therefore, the AChE needs to be reactivated to treat nicotinic manifestations of poisoning. Pralidoxime chloride (2-PAM CL), the only oxime commercially available in the United States, reactivates AChE by removing the organophosphoryl moiety but must be administered as soon as possible after exposure because, with time, the bond between the organophosphate and the AChE “ages,” permanently inhibiting the AChE. Nicotinic muscle weakness is reversed within a few minutes following intravenous administration of 50 mg/kg (1-5 g) of 2-PAM CL over 5 min.

Prophylaxis in anticipation of “nerve gas” exposure is usually achieved using pyridostigmine. The theory that pyridostigmine will occupy a percentage of receptors on AChE, preventing them from binding with organophosphates, has been demonstrated in experimental animals. However, data in humans are limited to our experience during the Gulf War. Many Gulf War veterans reported experiencing pyridostigmine-induced side effects (e.g., gastrointestinal upset); however, symptoms were generally mild, and combat and daily function were rarely compromised.

Anticholinergic poisoning

Inhibition of cholinergic function most often occurs because of ingestion of plants (Box 83-2) or foods that contain high concentrations of atropine or related compounds. Central anticholinergic effects are biphasic, beginning with central nervous system excitation followed by depression. Signs include fragmentary speech patterns, visual hallucinations, atypical behavior, ataxia, and fever. Peripheral anticholinergic effects include decreased saliva, sweat (further contributing to fever), and tearing. Other peripheral symptoms include loss of accommodation, blurred vision, mydriasis, tachycardia, and decreased gastrointestinal motility and urinary bladder tone. A mnemonic summarizes many central and peripheral effects of anticholinergic poisoning (Box 83-3).

Clinical considerations

Common causes of anticholinergic poisoning are eating the seeds or flowers of one of the plants listed in Box 83-2 or drinking a tea made from one or more of these plants. One historical treatment for asthma was to inhale the smoke from burning jimsonweed. The active ingredient in that folk remedy was ipratropium, a well-known antimuscarinic bronchodilator.